You just read:

Otsuka and Mylan Announce License Agreement to Commercialize Delamanid (Deltyba™) for Multidrug-Resistant Tuberculosis (MDR-TB) in High-Burden Countries

News provided by

Mylan N.V.

Aug 24, 2017, 03:00 ET